• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Verastem Inc.

    5/30/24 4:15:56 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VSTM alert in real time by email
    S-8 1 tm2415840d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on May 30, 2024

    Registration No. 333-    

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

    Verastem, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   27-3269467
    (State or other jurisdiction
    of incorporation or organization)
      (I.R.S Employer Identification No.)
         
    117 Kendrick St., Suite 500
    Needham, MA
      02494
    (Address of Principal Executive Offices)   (Zip Code)

     

    Amended and Restated 2021 Equity Incentive Plan

    (Full title of the plan)

     

    Daniel Paterson
    President and Chief Executive Officer
    Verastem, Inc.

    117 Kendrick St., Suite 500

    Needham, MA 02494

    (781) 292-4200

    (Name, address, and telephone number, including area code, of agent for service)

     

    With copies to:

    Marko S. Zatylny

    Ropes & Gray LLP

    Prudential Tower

    800 Boylston Street

    Boston, MA 02199

    (617) 951-7000

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ¨   Accelerated filer ¨
    Non-accelerated filer x   Smaller reporting company x
        Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. o

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 is being filed to register an additional 3,200,000 shares under the Registrant’s Amended and Restated 2021 Equity Incentive Plan. Pursuant to General Instruction E to Form S-8, the Registrant incorporates by reference, except to the extent supplemented, amended or superseded by the information set forth herein, into this Registration Statement the entire contents of its Registration Statements on Form S-8 (File No. 333-257111) filed with the Securities and Exchange Commission on June 15, 2021.

     

     

     

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 8. Exhibits.

     

    Exhibit   Description
    4.1   Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Annual Report on Form 10-K filed by the Registrant on March 12, 2019)
    4.2   Certificate of Amendment to the Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.2 to the Annual Report on Form 10-K filed by the Registrant on March 12, 2019)
    4.3   Certificate of Amendment to the Restated Certificate of Incorporation of Verastem, Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed by the Registrant with the Securities and Exchange Commission on May 21, 2020)
    4.4   Certificate of Amendment to the Restated Certificate of Incorporation of Verastem, Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed by the Registrant with the Securities and Exchange Commission on May 31, 2023)
    4.5   Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.4 to Amendment No. 3 to the Registration Statement on Form S-1 filed by the Registrant with the Securities and Exchange Commission on January 13, 2012)
    4.6   Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Form 8-K filed by the Registrant with the Securities and Exchange Commission on November 7, 2022)
    4.7   Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Form 8-K filed by the Registrant with the Securities and Exchange Commission on January 25, 2023)
    4.11   Amended and Restated 2021 Equity Incentive Plan (incorporated by reference to Appendix A of the Registrant’s Definitive Proxy Statement on Schedule 14A, filed by the Registrant with the Securities and Exchange Commission on April 12, 2024)
    5.1   Opinion of Ropes & Gray LLP (filed herewith)
    23.1   Consent of Ropes & Gray LLP (included in Exhibit 5.1)
    23.2   Consent of Ernst & Young LLP (filed herewith)
    24.1   Power of attorney (included on the signature page of this Registration Statement under the caption “Power of Attorney”)
    107   Filing Fee Table (filed herewith)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Needham, Commonwealth of Massachusetts on May 30, 2024.

     

      VERASTEM, INC.
         
      By: /s/ Daniel Paterson
        Daniel Paterson
        President and Chief Executive Officer

     

    POWER OF ATTORNEY

     

    Each person whose signature appears below constitutes and appoints Daniel Paterson and Daniel Calkins, and each of them singly, either of whom may act without the joinder of the other, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and other documents in connection therewith with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them singly, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or either of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.

     

    SIGNATURES   TITLE   DATE
    /s/ Daniel Paterson   President, Chief Executive Officer and Director   May 30, 2024
    Daniel Paterson   (Principal executive officer)    
             
    /s/ Daniel Calkins   Chief Financial Officer   May 30, 2024
    Daniel Calkins   (Principal financial and accounting officer)    
             
    /s/ Paul A. Bunn, M.D.   Director   May 30, 2024
    Paul A. Bunn, M.D.        
             
    /s/ Robert Gagnon   Director   May 30, 2024
    Robert Gagnon        
             
        Director   May 30, 2024
    John H. Johnson        
             
    /s/ Anil Kapur   Director   May 30, 2024
    Anil Kapur        
             
    /s/ Michael Kauffman   Director   May 30, 2024
    Michael Kauffman, M.D., Ph.D.        
             
    /s/ Michelle Robertson   Director   May 30, 2024
    Michelle Robertson        
             
    /s/ Eric Rowinsky, M.D.   Director   May 30, 2024
    Eric Rowinsky, M.D.        
             
    /s/ Brian Stuglik   Director   May 30, 2024
    Brian Stuglik        
             
    /s/ Karin Tollefson   Director   May 30, 2024
    Karin Tollefson        

     

     

     

    Get the next $VSTM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VSTM

    DatePrice TargetRatingAnalyst
    2/4/2026$18.00Buy
    H.C. Wainwright
    10/16/2025Overweight
    Cantor Fitzgerald
    4/10/2025$15.00Buy
    Jefferies
    3/24/2025$7.00 → $10.00Buy
    H.C. Wainwright
    12/31/2024$13.00 → $20.00Buy
    BTIG Research
    9/30/2024$13.00Buy
    Guggenheim
    11/21/2023$27.00Buy
    BTIG Research
    9/27/2023$21.00Buy
    B. Riley Securities
    More analyst ratings

    $VSTM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Paterson Dan sold $6,489 worth of shares (970 units at $6.69), decreasing direct ownership by 0.16% to 612,919 units (SEC Form 4)

    4 - Verastem, Inc. (0001526119) (Issuer)

    2/5/26 4:10:10 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Calkins Daniel was granted 16,665 shares, increasing direct ownership by 16% to 121,384 units (SEC Form 4)

    4 - Verastem, Inc. (0001526119) (Issuer)

    1/23/26 4:58:52 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Paterson Dan was granted 213,785 shares, increasing direct ownership by 53% to 613,889 units (SEC Form 4)

    4 - Verastem, Inc. (0001526119) (Issuer)

    1/23/26 4:57:26 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VSTM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Verastem with a new price target

    H.C. Wainwright initiated coverage of Verastem with a rating of Buy and set a new price target of $18.00

    2/4/26 8:31:21 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald resumed coverage on Verastem

    Cantor Fitzgerald resumed coverage of Verastem with a rating of Overweight

    10/16/25 8:50:56 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Verastem with a new price target

    Jefferies initiated coverage of Verastem with a rating of Buy and set a new price target of $15.00

    4/10/25 12:44:18 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VSTM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Rowinsky Eric K bought $7,680 worth of shares (2,000 units at $3.84) (SEC Form 4)

    4 - Verastem, Inc. (0001526119) (Issuer)

    1/24/24 4:00:39 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VSTM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers

    Based on preliminary, unaudited results, Verastem expects AVMAPKI™ FAKZYNJA™ CO-PACK net product revenues of approximately $17.5 million for the fourth quarter of 2025 and approximately $30.9 million for the full year 2025, following U.S. FDA approval in May 20251 Company plans to continue rapidly advancing clinical development program for VS-7375, a highly selective, oral KRAS G12D (ON/OFF) inhibitor with best-in-class potential, in several advanced KRAS G12D solid tumor indications Company sees preliminary unaudited cash, cash equivalents, and investments of $205 million as of December 31, 2025; pro-forma year-end cash, cash equivalents and investments of $234 million inclusive of net

    2/4/26 7:30:00 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors

    Issued on behalf of Oncolytics Biotech Inc. USANewsGroup.com News Commentary VANCOUVER, BC, Jan. 30, 2026 /PRNewswire/ -- The global oncology sector is rocketing toward $668 billion in 2034[1], partly fueled by a massive structural pivot toward gastrointestinal cancers where clinical velocity is finally shattering historical benchmarks. With the FDA's 2026 framework explicitly prioritizing accelerated pathways for platforms showing superior objective response rates and durability[2], a select group of innovators is unlocking the immunologically "cold" GI tumors that have baffled researchers for decades. This regulatory tailwind places Oncolytics Biotech Inc. (NASDAQ:ONCY), Pfizer (NYSE:PFE),

    1/30/26 10:19:00 AM ET
    $ONCY
    $PFE
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of stock options to purchase 73,000 shares of its common stock to eight new employees and the grant of 218,265 restricted stock units to nineteen new employees. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee's acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price equal to $6.88 per share, the closing price of Verastem Oncology's common stock as reported by Nasdaq on

    1/12/26 4:01:00 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VSTM
    SEC Filings

    View All

    Verastem Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Verastem, Inc. (0001526119) (Filer)

    2/4/26 7:30:33 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Verastem Inc.

    144 - Verastem, Inc. (0001526119) (Subject)

    1/14/26 5:15:00 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verastem Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Verastem, Inc. (0001526119) (Filer)

    1/8/26 4:16:07 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VSTM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Verastem Inc.

    SC 13G/A - Verastem, Inc. (0001526119) (Subject)

    11/14/24 6:25:40 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Verastem Inc.

    SC 13G/A - Verastem, Inc. (0001526119) (Subject)

    11/14/24 4:38:53 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Verastem Inc.

    SC 13G - Verastem, Inc. (0001526119) (Subject)

    11/14/24 4:36:17 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VSTM
    Financials

    Live finance-specific insights

    View All

    Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates

    Achieved AVMAPKI™ FAKZYNJA™ CO-PACK net product revenue of $11.2 million VS-7375 cleared first two monotherapy dose levels with no dose-limiting toxicities reported; no nausea, vomiting or diarrhea greater than Grade 1 were observed Enrollment initiated for VS-7375 in combination with cetuximab in patients with advanced KRAS G12D mutant solid tumors, including colorectal cancer Ended Q3 2025 with $137.7 million in cash and cash equivalents; with expected product revenue and exercise of cash warrants, Company cash runway would extend into the second half of 2026 Company to host a conference call and webcast today at 8:00 a.m. ET Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical compa

    11/4/25 7:30:00 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025

    Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its third quarter 2025 financial results and business updates on Tuesday, November 4, 2025, at 8:00 am ET. To access the conference call, please dial (888) 596-4144 (U.S.) or (646) 968-2525 (international) and enter the passcode 8194537 at least 10 minutes prior to the event start time. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, https://inv

    10/23/25 7:30:00 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates

    Achieved AVMAPKI™ FAKZYNJA™ CO-PACK net product revenue of $2.1 million in the first six weeks of launch First patient dosed in the U.S. trial for VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, in KRAS G12D advanced solid tumors Ended Q2 2025 with $164.3 million in cash and cash equivalents; with product revenue and exercise of cash warrants, Company has expected cash runway into the second half of 2026 Company to host a conference call and webcast today at 4:30 p.m. ET Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced business updates and reported financial results for

    8/7/25 4:05:00 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VSTM
    Leadership Updates

    Live Leadership Updates

    View All

    Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth

    John Johnson, current board member, appointed to chairman of the board Michael Kauffman, M.D., Ph.D., lead director since 2016, appointed to president of development Commercial launch progresses as RAMP 301 Phase 3 confirmatory trial in recurrent LGSOC completes additional patient enrollment; topline data anticipated in mid-2027 Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced strategic leadership changes to accelerate its next phase of growth. Michael Kauffman, M.D., Ph.D., currently lead director of the Board, has been appointed as the president of development and will jo

    12/15/25 4:01:00 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

    Avutometinib plus defactinib granted priority review by FDA in December 2024, under the accelerated approval pathway, for KRAS mutant recurrent LGSOC; PDUFA action date set for June 30, 2025 Filed an investigational new drug application in the U.S. for VS-7375, an oral KRAS G12D (ON/OFF) inhibitor RAMP 205 trial in 1L metastatic pancreatic cancer continues to progress with an additional dose cohort added and enrollment across all dose-level cohorts on track to complete in Q1 Company cash, cash equivalents, and investments of $88.8 million as of December 31, 2024; pro forma $151.3 million including debt refinancing and equity issuance with Oberland, and equity issuance under at-the-market

    3/20/25 4:01:00 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verastem Oncology Names Matthew E. Ros as Chief Operating Officer

    New executive leadership supports the company's transition to a fully integrated commercial-stage organization in a year of transformative growth with a potential new product launch in mid-2025. Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Matthew E. Ros as chief operating officer. In his role, Mr. Ros will report to Dan Paterson, president and chief executive officer, and will serve on the company's executive leadership team. "We are thrilled to welcome Matt to Verastem Oncology at an important time as we prepare for a mid-2025 product launch and th

    1/15/25 7:30:00 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care